Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. - Wikidata - awgldk - TriplyDB

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.

http://www.wikidata.org/entity/Q46760321

about

Dimethyl fumarate for multiple sclerosis Dimethyl fumarate for multiple sclerosis Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis Laquinimod therapy in multiple sclerosis: a comprehensive review The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders 12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function.The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications New approaches to treating Alzheimer's disease Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis.Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.Role of the Nrf2 signaling system in health and disease.Dimethyl Fumarate: A Review in Relapsing-Remitting MS.Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.Sex Bias in Pathogenesis of Autoimmune Neuroinflammation: Relevance for Dimethyl Fumarate Immunomodulatory/Anti-oxidant Action.Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials.T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis.Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers

P2860

Q24186433-C3BEBF70-9103-42BC-9A08-B21F6A3275F4 Q24197602-FE32F9D6-04B7-49FF-9CF3-368B74779BEE Q26738969-531F1336-3760-4664-9221-27238912EB84 Q26752859-A3978D87-0D49-4AE4-BCD1-4CA0826FCC85 Q28081636-3110E72F-C168-406C-A6CD-12FA564F4824 Q28086844-307C7D78-B355-471D-B8D4-0066422A230A Q28395641-5888E6B3-E194-4468-9B24-89CEF5C62D28 Q30371651-AAD9190C-840B-4590-BFCF-73114CB392A8 Q33621682-1E292A98-DD52-4955-A848-13DCCFF08B6B Q33970540-3E926151-DA3F-4F27-8CCE-FB94AC946867 Q35081742-3639E6DF-ABB3-4B7A-BF6F-8DB59CA7EFBE Q35115898-53401D8D-0AE2-4708-88BA-7E3B9619617A Q36154808-7C0D1ABE-717F-4F03-93C4-0566ABCC87AA Q36361543-E04EB53B-4674-4783-B8A2-CF224A160EC1 Q37343648-07C4C31F-DE77-4EEA-94C3-3E7EA7377B62 Q38195521-A1F4708B-604A-4C03-B0F4-05B8F1CD2394 Q38237494-5DA2A8A4-61C6-4187-B451-80C039FB1B2D Q38675014-A5B29872-E40F-4955-B458-3B90BB03E118 Q39100528-B37B82F7-C41E-4316-A728-CB9A74B9F912 Q40189763-3A82C313-DA42-4604-87F4-BC99C52CECEE Q40425312-104B59F4-EF78-4797-8789-D2A1FDD4B7B8 Q41197212-458DEAFE-3F57-4DC8-98A8-B694F4FF737B Q48088068-A5BA6084-9C47-4E57-B61C-18CD83B35EB5 Q58805531-42902AF9-093A-4B44-A9EA-2376BEAE75CB

P2860

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.

http://www.wikidata.org/entity/Q46760321

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Clinical efficacy of BG-12 (di ...... analyses of the DEFINE study.

@en

type

label

Clinical efficacy of BG-12 (di ...... analyses of the DEFINE study.

@en

prefLabel

Clinical efficacy of BG-12 (di ...... analyses of the DEFINE study.

@en

P1433

Q46760321-BC78D0B5-7FA4-460D-AAD4-F818EE3953BC

P1476

Q46760321-DFFF89F6-9128-4177-85F8-01BC15BD9407

P2093

Q46760321-44037F56-819F-4EC6-B8C6-5F2EC7F9361B

Q46760321-555AA203-F9A0-4D0B-9AD1-26D6918BDC15

Q46760321-8D1B60A1-91A7-44D8-B0CD-24267B3C3CC3

Q46760321-CA8C94CC-6243-440C-9ACF-FBBE377D8453

Q46760321-D03CCC03-E4A5-4376-AB14-07101B003A27

Q46760321-D65D6A00-B220-4DEF-A432-5313BDB1CFB2

Q46760321-D7B0404D-B5B9-4820-A5CE-41175E17D6DC

P2860

Q46760321-0343DE64-EE4E-4AE5-A66C-CB3C71196E54

Q46760321-122F17A3-734B-4ADC-BDB1-75AE9948614B

Q46760321-2DEB5ECE-EDDD-4BDE-90C1-0E12BA4F8EFD

Q46760321-2EB3DA38-4EDE-40B3-9D1B-5E341AA98425

Q46760321-3522A45D-E6E2-4EB8-818F-DBAF78C1E55A

Q46760321-49AF1318-7BF0-43DB-BC9D-5590CF1F6CB0

Q46760321-5973897B-2E45-4A9E-8D4E-0C568D785DF9

Q46760321-614615B6-7B8B-456A-B4DC-2FC0F472DDA1

Q46760321-632F187F-C141-4638-94DB-06FACDCE0DF3

Q46760321-7AE64563-1380-4799-AC78-437B3CFE5DC0

P2888

Q46760321-E58A158A-B5A3-4BFA-9712-59C83E3CC58F

P304

Q46760321-B5C41318-7403-4BF0-AF51-84822D4E4259

P31

Q46760321-314E8265-7B07-4450-8422-91DD0852067C

P356

Q46760321-D65074AA-495E-40F0-BC8A-C27710A17527

P433

Q46760321-BF136302-EDD1-421D-8F2F-D8C9F657F236

P478

Q46760321-13D2D785-A9E1-45E4-BFAA-5F1B612E4BAF

P50

Q46760321-28CF7395-1AED-45B0-8658-3C7A2B1A4471

Q46760321-9D8902E9-EBA2-4BD1-949A-1FF6D7F7712F

P577

Q46760321-69034E41-264E-43E8-84E9-6933863392E0

P698

Q46760321-F24ADA7F-B548-4D07-A11A-85B6767BA335

P921

Q46760321-530C3DF5-CF10-4BF5-AAC4-B618547D2D7C

P356

S00415-013-6954-7

P1433

Journal of Neurology

P1476

Clinical efficacy of BG-12 (di ...... analyses of the DEFINE study.

@en

P2093

Amit Bar-Or

http://www.w3.org/2001/XMLSchema#string

Douglas L Arnold

http://www.w3.org/2001/XMLSchema#string

John O'Gorman

http://www.w3.org/2001/XMLSchema#string

Katherine T Dawson

http://www.w3.org/2001/XMLSchema#string

Krzysztof Selmaj

http://www.w3.org/2001/XMLSchema#string

Monica Stephan

http://www.w3.org/2001/XMLSchema#string

Ralf Gold

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.

Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.

Clinical prognostic factors in multiple sclerosis: a natural history review.

Natural history of multiple sclerosis: early prognostic factors.

P2888

s00415-013-6954-7

P304

2297-2305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-013-6954-7

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

260

http://www.w3.org/2001/XMLSchema#string

P50

Gavin Giovannoni

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23797999

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis